Takeda Pharmaceutical Q4 Earnings Call Highlights

Takeda Pharmaceutical NYSE: TAK reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three expected product launches and a broader cost transformation program.

MarketBeat • 14 hours ago

Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring

Japan's Takeda Pharmaceutical , plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with ​a restructuring to centralize corporate functions and reduce ‌costs.

Reuters • May 13, 2026

Takeda Pharmaceutical Company Limited (TAK) Q4 2026 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (TAK) Q4 2026 Earnings Call Transcript

Seeking Alpha • May 13, 2026

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was parti.

Business Wire • May 13, 2026

Takeda's immune disease drug meets main goal of mid-to-late stage trial

Takeda Pharmaceutical ​said its ‌experimental drug ​for ​primary immunodeficiency disease, ⁠a ​rare condition ​that weakens the ​immune ​system, has met ‌the ⁠main goal of a ​mid- ​to ⁠late-stage ​clinical trial.

Reuters • May 4, 2026

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.

Business Wire • May 4, 2026

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Apr 30, 2026

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.

Zacks Investment Research • Apr 24, 2026

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Apr 14, 2026

My Top 4 Pharma Picks Under Rising Geopolitical Risk

Autoimmune diseases, oncology, and type 2 diabetes continue to spread around the world, but these stocks stay off investors' radars. Many of them consistently beat Street's consensus forecasts and offer dividend yields even higher than oil and gas stocks, as well as the "Magnificent 7." By opening this article, you will find out my "top 4 Big Pharma players."

Seeking Alpha • Apr 13, 2026